To examine the role of adhesion molecules in T cell recruitment and activation during allergen-induced late asthmatic response (LAR), we evaluated the expression of lymphocyte function-associated antigen-la (LFA-1a) and intercellular adhesion molecule-i (ICAM-1) on peripheral blood T lymphocyte subsets from atopic asthmatic patients and their changes following allergen inhalation challenge. 12 atopic asthmatic patients were studied. Six patients showed only a single early response after allergen challenge, and six developed a dual response. At baseline, dual responders (DR) had a significantly higher expression of ICAM-1 on CD4' and CD8' T lymphocytes as compared with both single early responders (P < 0.005 and P < 0.02, respectively) and controls (P < 0.001, both comparisons). Allergen challenge was followed by a decrease of CD8' ICAM-1l T lymphocytes in all DR (P < 0.05) and of CD4' ICAM-1l T lymphocytes in four out of six DR, at the time of the LAR. At the same time, a significant rise in serum levels of the soluble form of ICAM-1 was observed in DR. These results suggest that peripheral blood immunoregulatory T lymphocytes are in a higher state of activation in DR as compared with early responders. The upregulation of ICAM-1 on these cells may be important in enhancing airway inflammation in patients with LAR. (J. Clin. Invest. 1994.94:1840-1845
Introduction
There is increasing evidence that T lymphocytes play a central role in immune-inflammatory response in asthma. These cells recognize and respond directly to allergens and, through the release of several cytokines, may orchestrate the inflammatory response in asthma (1) . T lymphocyte activation has been demonstrated in peripheral blood in both stable and acute severe asthma (2) (3) (4) (5) and in bronchoalveolar lavage of patients with mild to moderate disease severity (5) (6) (7) . Activated T cells have also been identified in the bronchial mucosa of atopic asthmatics (8) .
A critical initial step in inflammatory cell migration from vascular compartments into the airways is the expression of cell surface adhesion molecules. A large number of these molecules have been identified and characterized in recent years (9) (10) (11) (12) .
Among T lymphocyte adhesion receptors, the heterodimer lymphocyte function-associated antigen-I (LFA-1)' and the intercellular adhesion molecule-i (ICAM-1) have been shown to play an important role not only in T cell recruitment, but also in T cell activation and in the development of specific immune responses (10, (13) (14) (15) (16) . LFA-1 is a member of the 62 family of integrins, which is constitutively expressed on most leukocytes (9) (10) (11) (12) (13) (14) . ICAM-1 is a cell adhesion molecule, belonging to the immunoglobulin supergene family, which is expressed on a variety of hemopoietic and nonhemopoietic cells, and is upregulated at sites of inflammation (10, 17, 18) . ICAM-1 is expressed only weakly on resting T lymphocytes, but activation of these cells by mitogens or specific cytokines increases its expression (15, (17) (18) (19) . Recent studies suggest that the interaction between ICAM-1 and LFA-l plays a role in the development of allergic airway inflammation (20) (21) (22) (23) (24) .
The allergen-induced late asthmatic response (LAR) may provide a useful model for investigating inflammatory events in atopic asthma. The LAR is associated with airway inflammation and it has been suggested that the recruitment and activation of inflammatory cells lead to local changes in the airways (25) (26) (27) (28) . Recent studies have demonstrated changes in T cell subsets in both peripheral blood and bronchoalveolar lavage after allergen challenge, suggesting a link between T lymphocyte function and the occurrence of the LAR (29) (30) (31) .
We speculated that enhanced expression of adhesion molecules on circulating T cells might be relevant to the selective recruitment and activation of these cells.
To test this hypothesis we evaluated the expression of LFAla and ICAM-1 on peripheral blood T cell subsets from atopic asthmatic patients with or without LAR and their changes following allergen inhalation challenge. Normal volunteers were evaluated as controls for baseline data. Moreover, as a soluble form of ICAM-1 has recently been described (32, 33) and shown to increase in acute asthma and other inflammatory conditions (34, 35) , we also determined the serum levels of the soluble form of ICAM-1 (s-ICAM-1) in asthmatic patients and control subjects.
Methods
Patients. 12 nonsmoking atopic asthmatic patients (7 men and 5 women), 16 to Flow cytometry Baseline data. The absolute numbers and the percentages of CD4' and CD8' T lymphocytes as well as the CD4/CD8 ratio did not differ in ER, DR, and control subjects at baseline (Table II) . The analysis of adhesion molecule expression on T lymphocyte subsets showed that dual asthmatic responders had a significantly higher percentage of CD4' T lymphocytes expressing ICAM-1 when compared with single early responders (P < 0.005) and control subjects (P < 0.001); in contrast, no significant differences were observed between the latter two groups (Fig. 1 A) . Even if to a lesser extent, the percentage of CD8' T lymphocytes expressing ICAM-1 was also significantly higher in dual asthmatic responders, compared with single responders (P < 0.02) and control subjects (P < 0.001). No significant differences were observed between ER and control subjects (Fig. 1 B) .
Baseline values of both CD4' ICAM-lI and CD8' ICAM-1 + subpopulations from the overall asthmatic patients were significantly related to the changes in FEV, at the time of the LAR (r = 0.636, P < 0.03 and r = 0.629, P < 0.03, respectively), whereas no correlations were observed with baseline FEVI, PD20 methacholine, or PD20 allergen.
As shown in Table Ill Data after challenge. After allergen challenge, the percentage of CD8+ T lymphocytes expressing ICAM-1 significantly decreased in dual asthmatic responders, at 6 h, compared with baseline values and values at 15 min (P < 0.05 for both comparisons) (Fig. 2) . However, no correlation was found between changes of CD8+ ICAM-l T lymphocytes and FEV1 changes at the time of the LAR.
There was a remarkable decrease in the percentage of CD4+ ICAM-I' T lymphocytes in four out of six dual responders at 6 h after challenge. However, the decrease did not reach statistical significance in the overall population of DR. No significant changes in the percentage of CD4+ ICAM-1+ and CD8+ ICAM-1+ T lymphocytes were observed after challenge in patients with single early response (Fig. 2) .
The absolute numbers and the percentages of CD4+ and CD8+ T lymphocytes as well as the CD4/CD8 ratio did not change, after allergen challenge, either in ER or DR (Table II) . Similarly, no changes were observed in the percentage of CD4+ or CD8+ T lymphocytes expressing LFA-la (Table III) .
s-ICAM-J assay
Baseline serum levels of s-ICAM-l were not significantly different between the two groups of asthmatic patients. Similarly, (Fig. 3) .
Discussion
This study was designed to evaluate the expression of the adhesion molecules LFA-la and ICAM-1 on peripheral blood T lymphocyte subsets from atopic asthmatic patients and their changes after allergen inhalation challenge. The main findings are: (a) dual asthmatic responders, at baseline, had an increased expression of ICAM-1 on CD4' T lymphocytes and, to a lesser extent, on CD8' T lymphocytes as compared with both single early responders and control subjects, and (b) allergen challenge was followed by a marked decrease of CD8' ICAM-1+ T lymphocytes in all DR and of CD4' ICAM-1+ T lymphocytes in four out of six DR at the time of the LAR. At the same time, a significant rise in serum levels of the soluble form of ICAM-1 occurred in dual asthmatic responders.
ICAM-1 is a cell adhesion molecule expressed on a variety of hemopoietic and nonhemopoietic cells, and upregulated by inflammatory mediators (10, 15, (17) (18) (19) . It is the counterreceptor for the leukocyte integrins LFA-1 and Mac-i (38) (39) (40) (41) . The relevance of ICAM-1/LFA-1 interaction in the development of allergic airway inflammation is provided by the observation that anti-ICAM-1 monoclonal antibodies are able to inhibit both inflammatory cell infiltrate and acquired bronchial hyperresponsiveness accompanying repeated allergen challenge in nonhuman primate models (20) . Furthermore, in nasal biopsies from patients with perennial allergic rhinitis, ICAM-1 expression on endothelial cells was shown to be significantly increased, compared with healthy controls (23) . Upregulation of ICAM-1 has also been observed in human skin 6 h after local intradermal challenge, in association with tissue eosinophilia (42) . not only is required for cell adhesion and migration, but also plays a key role in the immune response; in fact, these adhesion molecules are involved in leukocyte functions such as antigenspecific recognition by T lymphocytes, T lymphocyte activation, and Ig production through T-dependent humoral immune responses (10, (13) (14) (15) (16) The late phase asthmatic response is associated with airway inflammation (25) (26) (27) and is characterized by an inflammatory cell infiltrate in the bronchial mucosa and submucosa (28) . The upregulation of ICAM-1 on immunoregulatory T cells in peripheral blood might be the consequence of cytokine release from activated airway inflammatory cells or it might reflect a more prolonged antigenic stimulation in patients with dual asthmatic response. As an alternative explanation, it might be the result of a "spill-over" of activated cells from the airways into vascular compartments. Regardless, the upregulation of ICAM-1 on T cells may play an important role in enhancing and maintaining airway inflammation in patients with LAR. In fact, increased interactions between these cells and antigen-presenting cells or other lymphocytes could lead to chronic inflammation mediated by immunocompetent cell activation and cytokine release.
After allergen challenge, we observed a decrease of CD8+ ICAM-l+ T lymphocytes in all dual asthmatic responders, and of CD4+ ICAM-1+ T lymphocytes in four out of six dual asthmatic responders, at the time of the LAR. The decrease of ICAM-1 expression on T lymphocyte subsets might be the consequence of ICAM-1 shedding from activated cells, as the soluble form of ICAM-1 increases in serum of DR at the time of the LAR. This latter observation is consistent with the results of previous studies showing that atopic patients undergoing segmental bronchoprovocation with antigen have s-ICAM-1 present in bronchoalveolar lavage fluid only during the late response (43) . A significant elevation of circulating s-ICAM-l was also shown in patients with acute asthma when compared to stable asthmatics and control subjects (34) . As an alternative explanation, the decrease of CD8' ICAM-1+ and CD4' ICAM-1+ T lymphocytes at the time of the LAR might reflect the migration of activated T cells from the vascular compartment into the airways; this latter possibility seems less likely since both the numbers and the percentages of CD8' and CD4' T lymphocytes did not change after allergen inhalation challenge. However, as our study was performed only on peripheral blood we cannot exclude the possibility that the decrease of both CD8' and CD4' T lymphocytes expressing ICAM-1 reflects the migration of these cells into the airways.
In this study we (29) . The first group of investigators, in fact, found that allergen inhalation by subjects exhibiting a single early response was associated with a significant elevation in the percentage, but not in the absolute number of CD4' T lymphocytes in the blood. Gerblich et al., in contrast, showed a decrease in peripheral blood CD4' T lymphocytes in atopic asthmatic patients after allergen challenge, but none of their patients showed LAR. These discrepancies can probably be explained by the different study design, particularly with respect to (a) the technique of allergen challenge, (b) the different time points studied, and (c) the different disease severity of the population studied.
In conclusion, this study shows that, in dual asthmatic responders, ICAM-1 is upregulated on peripheral blood immunoregulatory T lymphocytes and particularly on CD4' T lymphocytes, suggesting that these cells are in a higher state of activation in dual asthmatic responders, compared with single early responders. These results support the concept that more severe inflammatory changes occur in patients with LAR and add further evidence for an important role of adhesion molecules in immune and inflammatory response in asthma.
